scholarly journals Longitudinal and secular trends in total cholesterol levels and impact of lipid-lowering drug use among Norwegian women and men born in 1905–1977 in the population-based Tromsø Study 1979–2016

BMJ Open ◽  
2017 ◽  
Vol 7 (8) ◽  
pp. e015001 ◽  
Author(s):  
Laila Arnesdatter Hopstock ◽  
Kaare Harald Bønaa ◽  
Anne Elise Eggen ◽  
Sameline Grimsgaard ◽  
Bjarne K Jacobsen ◽  
...  

ObjectivesElevated blood cholesterol is a modifiable risk factor for cardiovascular disease. Cholesterol level surveillance is necessary to study population disease burden, consider priorities for prevention and intervention and understand the effect of diet, lifestyle and treatment. Previous studies show a cholesterol decline in recent decades but lack data to follow individuals born in different decades throughout life.MethodsWe investigated changes in age-specific and birth cohort-specific total cholesterol (TC) levels in 43 710 women and men born in 1905–1977 (aged 20–95 years at screening) in the population-based Tromsø Study. Fifty-nine per cent of the participants had more than one and up to six repeated TC measurements during 1979–2016. Linear mixed models were used to test for time trends.ResultsMean TC decreased during 1979–2016 in both women and men and in all age groups. The decrease in TC in age group 40–49 years was 1.2 mmol/L in women and 1.0 mmol/L in men. Both the 80th and the 20th percentile of the population TC distribution decreased in both sexes and all age groups. Longitudinal analysis showed that TC increased with age to a peak around middle age followed by a decrease. At any given age, TC significantly decreased with increase in year born. Lipid-lowering drug use was rare in 1994, increased thereafter, but was low (<3% in women and <5% in men) among those younger than 50 years in all surveys. Between 1994 and 2016, lipid-lowering drug treatment in individuals 50 years and older explained 21% and 28% of the decrease in TC levels in women and men, respectively.ConclusionsWe found a substantial decrease in mean TC levels in the general population between 1979 and 2016 in all age groups. In birth cohorts, TC increased with age to a peak around middle age followed by a decrease.

2018 ◽  
Vol 11 (12) ◽  
pp. 779-788 ◽  
Author(s):  
Alison M. Mondul ◽  
Corinne E. Joshu ◽  
John R. Barber ◽  
Anna E. Prizment ◽  
Nrupen A. Bhavsar ◽  
...  

Drug Safety ◽  
2006 ◽  
Vol 29 (10) ◽  
pp. 911-1010
Author(s):  
G. Trifir?? ◽  
V. Arcoraci ◽  
S. Moretti ◽  
D.U. Tari ◽  
M. Alacqua ◽  
...  

2002 ◽  
Vol 36 (12) ◽  
pp. 1957-1960 ◽  
Author(s):  
Aukje K Mantel-Teeuwisse ◽  
Olaf H Klungel ◽  
Ron MC Herings ◽  
Eugène P van Puijenbroek ◽  
Arijan J Porsius ◽  
...  

OBJECTIVE: To estimate the number of expected cases of myopathy based on the prevalence of lipid-lowering drug use, and to compare this number with the observed number of cases of myopathy due to lipid-lowering drug use in the Netherlands. METHODS: Prevalence of lipid-lowering drug use in 1998 was estimated by using data from the PHARMO record linkage system comprising pharmacy records linked to hospital admission data. The expected number of cases of myopathy was calculated by multiplying the total number of person-years of lipid-lowering drug use by the excess incidence rates of myopathy due to those drugs as reported in the literature. The observed number of cases was obtained from PHARMO and the Dutch Pharmacovigilance Foundation Lareb. RESULTS: Based on the estimated prevalence of lipid-lowering drug use in the Netherlands in 1998 (n = 520 800), we expected 60 cases of idiopathic myopathy due to hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) or fibric acid derivatives (fibrates). This low number was confirmed by data from PHARMO (n = 11; none of these were related to current use of lipid-lowering drugs) and Lareb (n = 43). CONCLUSIONS: The expected number of statin- or fibrate-related idiopathic myopathy is low and observed numbers are even lower in the Netherlands. This should, therefore, not compromise continued use of lipid-lowering drugs.


2002 ◽  
Vol 53 (4) ◽  
pp. 379-385 ◽  
Author(s):  
Aukje K. Mantel-Teeuwisse ◽  
Olaf H. Klungel ◽  
W. M. Monique Verschuren ◽  
Arijan J. Porsius ◽  
Anthonius De Boer

Neurology ◽  
2006 ◽  
Vol 67 (8) ◽  
pp. 1403-1410 ◽  
Author(s):  
D. Deplanque ◽  
I. Masse ◽  
C. Lefebvre ◽  
C. Libersa ◽  
D. Leys ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document